Clinical Trials

62 enrolled

Carcinoma, Hepatocellular

NCT07272265 2025-12-09

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Phase NA Completed

300 enrolled

Carcinoma, Hepatocellular

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

341 enrolled 28 charts

Pancreatic Adenocarcinoma

NCT05052099 2025-09-29

COMBATBIL

20 enrolled

Biliary Tract Neoplasms

NCT04487067 2025-09-22

AMETHISTA

Phase 3 Completed

152 enrolled 16 charts

Carcinoma, Hepatocellular

NCT05197504 2025-09-05

HCC

Completed

166 enrolled

Carcinoma, Hepatocellular

NCT03289962 2025-07-04

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

272 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03519295 2025-06-27

SCARCE

97 enrolled

Anus Neoplasms

NCT05750030 2025-05-06

FMT in IT-refractory HCC - FAB-HCC Pilot Study

12 enrolled

Carcinoma, Hepatocellular

NCT02876510 2025-02-04

ACTolog

GastrointestinalGynecologicHead & NeckThoracic

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT03127007 2025-01-22

R-IMMUNE

45 enrolled

Rectal Neoplasms

NCT05007613 2025-01-01

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

24 enrolled

Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Metastasis

NCT03946358 2024-12-20

VolATIL

GastrointestinalGynecologicHead & Neck

47 enrolled

Anal Canal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms

NCT04713891 2024-09-24

A Study of KF-0210 in Advanced Solid Tumors Patients

GastrointestinalGenitourinaryThoracic

14 enrolled

Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Lung Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02873195 2024-08-23

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

133 enrolled 13 charts

Colorectal Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

GastrointestinalGenitourinary

673 enrolled 22 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT04677504 2024-07-03

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

162 enrolled 18 charts

Biliary Tract Neoplasms

NCT03256344 2024-05-14

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

36 enrolled 16 charts

BreastGastrointestinal

Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02291289 2024-05-06

MODUL

1,044 enrolled 21 charts

Colorectal Neoplasms

NCT03650348 2024-04-22

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

BreastGastrointestinalGenitourinaryOther solid neoplasm

41 enrolled

HER2-positive Breast Cancer

NCT03201458 2024-04-05

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

86 enrolled 16 charts

Gallbladder Neoplasms, Cholangiocarcinoma

NCT03698461 2024-01-31

CLIMB

20 enrolled

558 enrolled 48 charts 3 FDA

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT03434379 2023-10-23

IMbrave150

Phase 3 Completed

Carcinoma, Hepatocellular

NCT03721653 2023-10-12

AtezoTRIBE

218 enrolled

Colorectal Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

37 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Completed

1,758 enrolled

BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03087864 2020-05-11

PERFECT

40 enrolled

Esophageal Neoplasms

NCT02788279 2019-12-11

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Phase 3 Completed

363 enrolled 19 charts

Colorectal Neoplasms

NCT02876224 2019-08-13

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

51 enrolled